Cargando…

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine

Detalles Bibliográficos
Autores principales:	Saito, Kazuyuki, Shimizu, Taro, Suzuki-Inoue, Katsue, Ishida, Tatsuhiro, Wada, Yoshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354782/ https://www.ncbi.nlm.nih.gov/pubmed/34378098 http://dx.doi.org/10.1007/s10072-021-05543-1

Ejemplares similares

Spinal cord ischemia complicating BNT162b2 mRNA COVID-19 vaccination
por: Fotiadou, Aggeliki, et al.
Publicado: (2022)

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
por: Trimboli, Michele, et al.
Publicado: (2021)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
por: Tanzilli, Antonio, et al.
Publicado: (2022)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2
por: Umezawa, Shu, et al.
Publicado: (2022)

Aseptic meningitis after BNT-162b2 COVID-19 vaccination
por: Chan, Amanda CY., et al.
Publicado: (2021)

Guillain–Barré syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea
por: Kim, Namkyun, et al.
Publicado: (2022)

Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
por: Kang, Yu Min, et al.
Publicado: (2021)

Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
por: Consoli, Stefano, et al.
Publicado: (2021)

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis following third dose of BNT162b2 COVID-19 vaccine in a patient with systemic lupus erythematosus
por: Kang, Minsung, et al.
Publicado: (2023)

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
por: Iannone, Michela, et al.
Publicado: (2021)

Steroid-responsive aseptic meningitis after BNT162b2 SARS-CoV-2 vaccine
por: Reis Carneiro, D., et al.
Publicado: (2022)

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
por: Kerr, Steven, et al.
Publicado: (2022)

Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2022)

Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?
por: Haji, Alhan, et al.
Publicado: (2023)

Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
por: Risma, Kimberly A., et al.
Publicado: (2021)

Herpes zoster and alopecia areata following mRNA BNT162b2 COVID‐19 vaccine: Controversial immune effects
por: Martora, Fabrizio, et al.
Publicado: (2022)

Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19
por: Kang, Kyusik, et al.
Publicado: (2022)

Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination
por: Yagi, Yohsuke, et al.
Publicado: (2021)

Clinicopathological features of cutaneous reactions after mRNA‐based COVID‐19 vaccines
por: Tihy, M., et al.
Publicado: (2021)

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
por: van Leeuwen, Leanne P.M., et al.
Publicado: (2022)

A case of anti-MOG antibody-positive ADEM following COVID-19 mRNA vaccination
por: Miyamoto, Katsuichi, et al.
Publicado: (2022)

Comments on “Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19”
por: Finsterer, Josef
Publicado: (2023)

Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
por: Dror, Amiel A., et al.
Publicado: (2021)

Aseptic Meningitis and mRNA Coronavirus Disease 2019 Vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA-based COVID-19 vaccines immunization
por: Meyer-Szary, Jaroslaw, et al.
Publicado: (2022)

New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series
por: Fanella, Gaia, et al.
Publicado: (2022)

Shingles and mRNA COVID‐19 vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
por: Rama, Tiago Azenha, et al.
Publicado: (2021)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort
por: Nguyen, Vincent Grigori, et al.
Publicado: (2023)

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
por: Marasco, Vincenzo, et al.
Publicado: (2021)

Reply: Aseptic Meningitis and mRNA Coronavirus Disease 2019 Vaccine
por: Heo, Sang Taek
Publicado: (2022)

Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia
por: Santi, Theresia, et al.
Publicado: (2022)

Laboratory-Confirmed SARS-CoV-2 Following One or More Doses of mRNA Vaccine Among Care Team Members at an Academic Health System
por: Curry, Scott, et al.
Publicado: (2021)

Parental concerns about COVID-19 vaccine safety and hesitancy in Korea: implications for vaccine communication
por: Cho, Hye-Kyung, et al.
Publicado: (2022)

Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign
por: Mattiuzzi, Camilla, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_im83pnec660if3ima9ukbtqr31